US Liquid Biopsy Testing Market Canvassed in New Renub Research Report Available at MarketPublishers.com
02 Feb 2016 • by Natalie Aster
LONDON – The screening tests segment is expected to become one of the largest share in the US market for liquid biopsy testing.
In the meantime, prostate cancer forms the most popular segment of the US marketplace, while lung cancer liquid biopsy screening is the less popular one.
Personalized therapies and technical advancements, growth in demand for minimally-invasive biopsy techniques are amongst key factors encouraging growth of this market.
New research study “United States – Liquid Biopsy Potential Testing Market & Volume Analysis to 2020” elaborated by Renub Research offers an up-close look at the US market for liquid biopsy testing. The report provides a 360-degree of this fast-evolving marketplace. It concentrates on the market potential and discloses a liquid biopsy potential test volume. The study sheds light on market shares and investigates the marketplace by cancer types. The research report explores recent developments in the field and analyzes major deals. It investigates driving forces and challenges of the US market. The research report also comprises forecast figures related to the marketplace.
United States – Liquid Biopsy Potential Testing Market & Volume Analysis to 2020
Published: January, 2016
Price: US$ 900.00
- detailed market overview;
- investigation of the most recent market developments;
- data on market drivers and challenges;
- coverage of all market segments;
- future market outlook;
- and more.
More new studies by this publisher are available at Renub Research page.